Medincell to Host Videoconference on May 15, 2024, at 10

30 AM CEST to Discuss Company's Latest News, Outlook, and R&D Activities

Regulatory News:

Medincell (Paris:MEDCL) is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. The first treatment based on BEPO technology, aimed at treating schizophrenia, was approved by the FDA in April 2023, and has since been distributed in the United States by Teva under the name UZEDY (BEPO technology is licensed to Teva under the name SteadyTeq).

Two other treatments are currently in Phase 3 clinical trials, including mdc-TJK, also developed with Teva, whose positive efficacy results were announced on May 8, 2024 (press release).

Medincell also announced on April 16, 2024, a co-development and licensing agreement with the American pharmaceutical group AbbVie, covering the development of 6 products (press release).

For strategic reasons, the Company has decided to terminate the mdc-GRT program (tacrolimus, transplantation) which was in the preclinical stage.

About Medincell

Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY (BEPO technology is licensed to Teva under the name SteadyTeq). We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities.

UZEDY and SteadyTeq are trademarks of Teva Pharmaceuticals

www.medincell.com

This press release contains forward-looking statements, including statements regarding Company’s expectations for (i) the timing, progress and outcome of its clinical trials; (ii) the clinical benefits and competitive positioning of its product candidates; (iii) its ability to obtain regulatory approvals, commence commercial production and achieve market penetration and sales; (iv) its future product portfolio; (v) its future partnering arrangements; (vi) its future capital needs, capital expenditure plans and ability to obtain funding; and (vii) prospective financial matters regarding our business. Although the Company believes that its expectations are based on reasonable assumptions, any statements other than statements of historical facts that may be contained in this press release relating to future events are forward-looking statements and subject to change without notice, factors beyond the Company's control and the Company's financial capabilities.